Stanley J. Meresman Sells 10,000 Shares of Guardant Health Inc (NASDAQ:GH) Stock

Share on StockTwits

Guardant Health Inc (NASDAQ:GH) Director Stanley J. Meresman sold 10,000 shares of Guardant Health stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $76.36, for a total transaction of $763,600.00.

Shares of GH traded up $1.11 during mid-day trading on Tuesday, reaching $76.09. The company’s stock had a trading volume of 14,435 shares, compared to its average volume of 1,083,396. The stock has a market cap of $7.20 billion and a PE ratio of -26.86. Guardant Health Inc has a 52 week low of $27.04 and a 52 week high of $112.21. The company’s fifty day moving average price is $92.05 and its two-hundred day moving average price is $82.42.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.21. The firm had revenue of $53.98 million during the quarter, compared to analyst estimates of $35.97 million. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The business’s quarterly revenue was up 178.5% on a year-over-year basis. During the same period in the previous year, the business posted ($1.75) EPS. As a group, sell-side analysts expect that Guardant Health Inc will post -1.27 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Advantage Investment Management LLC lifted its holdings in shares of Guardant Health by 200.0% in the 2nd quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock worth $39,000 after acquiring an additional 300 shares during the last quarter. HM Payson & Co. bought a new stake in shares of Guardant Health in the 2nd quarter worth approximately $43,000. Oppenheimer Asset Management Inc. bought a new stake in Guardant Health during the 2nd quarter valued at $62,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Guardant Health during the 2nd quarter valued at $76,000. Finally, FNY Investment Advisers LLC raised its holdings in Guardant Health by 7,816.7% during the 2nd quarter. FNY Investment Advisers LLC now owns 950 shares of the company’s stock valued at $82,000 after buying an additional 938 shares during the last quarter. Hedge funds and other institutional investors own 81.40% of the company’s stock.

GH has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Canaccord Genuity reiterated a “buy” rating and set a $125.00 target price (up from $96.00) on shares of Guardant Health in a research report on Wednesday, August 7th. Zacks Investment Research lowered shares of Guardant Health from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, Cowen set a $110.00 target price on shares of Guardant Health and gave the company a “buy” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $111.80.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

See Also: Are we seeing the beginning of a new bubble?

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

DeDora Capital Inc. Sells 9 Shares of Alphabet Inc
DeDora Capital Inc. Sells 9 Shares of Alphabet Inc
Amgen, Inc.  Position Lifted by DeDora Capital Inc.
Amgen, Inc. Position Lifted by DeDora Capital Inc.
DeDora Capital Inc. Purchases Shares of 3,935 SPDR Gold Shares
DeDora Capital Inc. Purchases Shares of 3,935 SPDR Gold Shares
DeDora Capital Inc. Sells 496 Shares of Nike Inc
DeDora Capital Inc. Sells 496 Shares of Nike Inc
Vanguard Dividend Appreciation ETF  Stock Position Lifted by Flagship Harbor Advisors LLC
Vanguard Dividend Appreciation ETF Stock Position Lifted by Flagship Harbor Advisors LLC
Pedevco  Stock Price Crosses Above 50 Day Moving Average of $0.00
Pedevco Stock Price Crosses Above 50 Day Moving Average of $0.00


© 2006-2019 Ticker Report